Please use this identifier to cite or link to this item:
Title: Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis.
Authors: Alonso, Cristina
Fernández-Ramos, David
Varela-Rey, Marta
Martínez-Arranz, Ibon
Navasa, Nicolás
Van Liempd, Sebastiaan M
Lavín Trueba, José L
Mayo, Rebeca
Ilisso, Concetta P
de Juan, Virginia G
Iruarrizaga-Lejarreta, Marta
delaCruz-Villar, Laura
Mincholé, Itziar
Robinson, Aaron
Crespo, Javier
Martín-Duce, Antonio
Romero-Gómez, Manuel
Sann, Holger
Platon, Julian
Van Eyk, Jennifer
Aspichueta, Patricia
Noureddin, Mazen
Falcón-Pérez, Juan M
Anguita, Juan
Aransay, Ana M
Martínez-Chantar, María Luz
Lu, Shelly C
Mato, José M
Keywords: 1-Carbon Metabolism;Lipid Metabolism;Mouse Model;Prognostic
metadata.dc.subject.mesh: Adult
Fatty Acids
Lipid Metabolism
Methionine Adenosyltransferase
Mice, Inbred C57BL
Mice, Knockout
Middle Aged
Non-alcoholic Fatty Liver Disease
Issue Date: 26-Jan-2017
Abstract: Nonalcoholic fatty liver disease (NAFLD) is a consequence of defects in diverse metabolic pathways that involve hepatic accumulation of triglycerides. Features of these aberrations might determine whether NAFLD progresses to nonalcoholic steatohepatitis (NASH). We investigated whether the diverse defects observed in patients with NAFLD are caused by different NAFLD subtypes with specific serum metabolomic profiles, and whether these can distinguish patients with NASH from patients with simple steatosis. We collected liver and serum from methionine adenosyltransferase 1a knockout (MAT1A-KO) mice, which have chronically low levels of hepatic S-adenosylmethionine (SAMe) and spontaneously develop steatohepatitis, as well as C57Bl/6 mice (controls); the metabolomes of all samples were determined. We also analyzed serum metabolomes of 535 patients with biopsy-proven NAFLD (353 with simple steatosis and 182 with NASH) and compared them with serum metabolomes of mice. MAT1A-KO mice were also given SAMe (30 mg/kg/day for 8 weeks); liver samples were collected and analyzed histologically for steatohepatitis. Livers of MAT1A-KO mice were characterized by high levels of triglycerides, diglycerides, fatty acids, ceramides, and oxidized fatty acids, as well as low levels of SAMe and downstream metabolites. There was a correlation between liver and serum metabolomes. We identified a serum metabolomic signature associated with MAT1A-KO mice that also was present in 49% of the patients; based on this signature, we identified 2 NAFLD subtypes. We identified specific panels of markers that could distinguish patients with NASH from patients with simple steatosis for each subtype of NAFLD. Administration of SAMe reduced features of steatohepatitis in MAT1A-KO mice. In an analysis of serum metabolomes of patients with NAFLD and MAT1A-KO mice with steatohepatitis, we identified 2 major subtypes of NAFLD and markers that differentiate steatosis from NASH in each subtype. These might be used to monitor disease progression and identify therapeutic targets for patients.
metadata.dc.identifier.doi: 10.1053/j.gastro.2017.01.015
Appears in Collections:Producción 2020

Files in This Item:
There are no files associated with this item.

This item is protected by original copyright

Except where otherwise noted, Items on the Andalusian Health Repository site are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives License.